Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Joo Kyung Park

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-9652-5287; OpenAlex author ID A5081474622. Sources: OpenAlex.

Their work

Papers
35 (first author 2, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
97
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 2 papers · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 3 papers · 2019: none · 2020: 4 papers · 2021: 3 papers · 2022: 4 papers · 2023: 4 papers · 2024: 3 papers · 2025: 3 papers · 2026: 1 paper

Papers 35

  1. Sex-specific prognostic value of triceps skinfold thickness and albumin in pancreatic cancer. Last author DOI 10.1016/j.isci.2026.115290↗
  2. Artificial Intelligence-Powered Spatial Analysis of Immune Phenotypes in Resected Pancreatic Cancer. Last author DOI 10.1001/jamasurg.2025.1999↗
  3. Skeletal Muscle Index Changes on Locoregional Treatment Application After FOLFIRINOX and Survival in Pancreatic Cancer. Co-author DOI 10.1002/jcsm.13643↗
  4. Evaluation of Exosome-derived Small RNAs as Potential Biomarkers for Pancreatic Ductal Adenocarcinoma Using Next-generation Sequencing. Last author DOI 10.3343/alm.2025.0121↗
  5. Impact and optimal timing of local therapy addition in borderline resectable or locally advanced pancreatic cancer after FOLFIRINOX chemotherapy. Co-author DOI 10.1016/j.ctro.2024.100732↗
  6. Establishment of a patient-specific avatar organoid model derived from EUS-guided fine-needle biopsy for timely clinical application in pancreatic ductal adeno… Last author DOI 10.1016/j.gie.2024.02.021↗
  7. Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma an… Co-author DOI 10.1186/s12943-024-02003-0↗
  8. Multi-biomarker panel prediction model for diagnosis of pancreatic cancer. Co-author DOI 10.1002/jhbp.986↗
  9. Lysosomal Storage Dysfunction, a Germline Variants Affecting Pancreatic Ductal Adenocarcinoma Development and Progression Last author DOI 10.1101/2023.02.15.23286007↗
  10. Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12967-023-04549-x↗
  11. Lysosomal Storage Dysfunction, a Germline Variants Affecting Pancreatic Ductal Adenocarcinoma Development and Progression Co-author DOI 10.21203/rs.3.rs-2578124/v1↗
  12. Clinical significance of circulating tumor cells after chemotherapy in unresectable pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.tranon.2021.101321↗
  13. Increased risk of pancreatic cancer in individuals with non-alcoholic fatty liver disease. Last author DOI 10.1038/s41598-022-14856-w↗
  14. The Feasibility of Stereotactic Body Proton Beam Therapy for Pancreatic Cancer. Co-author DOI 10.3390/cancers14194556↗
  15. Clinical Clues of Pre-Symptomatic Pancreatic Ductal Adenocarcinoma Prior to Its Diagnosis: A Retrospective Review of CT Scans and Laboratory Tests. Last author DOI 10.3390/clinpract12010008↗
  16. Accurate Prognosis Prediction of Pancreatic Ductal Adenocarcinoma Using Integrated Clinico-Genomic Data of Endoscopic Ultrasound-Guided Fine Needle Biopsy. Co-author DOI 10.3390/cancers13112791↗
  17. Diagnostic model for pancreatic cancer using a multi-biomarker panel. Co-author DOI 10.4174/astr.2021.100.3.144↗
  18. CORRIGENDUM: Addition of data source: Diagnostic model for pancreatic cancer using a multi-biomarker panel. Co-author DOI 10.4174/astr.2021.100.4.252↗
  19. Primary and Metastatic Pancreatic Cancer Cells Exhibit Differential Migratory Potentials. Co-author DOI 10.1097/mpa.0000000000001459↗
  20. Multi-Biomarker Panel Prediction Model for Diagnosis of Pancreatic Cancer: a retrospective and multi-center cohort study Co-author DOI 10.21203/rs.3.rs-76136/v1↗
  21. Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker. Last author DOI 10.3389/fonc.2020.616440↗
  22. Factors of Endoscopic Ultrasound-Guided Tissue Acquisition for Successful Next-Generation Sequencing in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.5009/gnl19011↗
  23. Preoperative EUS-guided FNA: effects on peritoneal recurrence and survival in patients with pancreatic cancer. Co-author DOI 10.1016/j.gie.2018.06.024↗
  24. Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients. First author DOI 10.1038/s41598-018-30100-w↗
  25. Correction: Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel. Co-author DOI 10.18632/oncotarget.24175↗
  26. KRAS mutation analysis of washing fluid from endoscopic ultrasound-guided fine needle aspiration improves cytologic diagnosis of pancreatic ductal adenocarcino… Co-author DOI 10.18632/oncotarget.13864↗
  27. Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel. Co-author DOI 10.18632/oncotarget.21861↗
  28. The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.12057↗
  29. Lower maximum standardized uptake value of fluorine-18 fluorodeoxyglucose positron emission tomography coupled with computed tomography imaging in pancreatic d… First author DOI 10.1016/j.amjsurg.2014.06.038↗
  30. Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 p… Co-author DOI 10.1371/journal.pone.0078977↗
  31. Chemosensitivity induced by down-regulation of microRNA-21 in gemcitabine-resistant pancreatic cancer cells by indole-3-carbinol. Co-author PMID 23564788↗
  32. Sonic Hedgehog in pancreatic cancer: from bench to bedside, then back to the bench. Co-author DOI 10.1016/j.surg.2012.05.030↗
  33. The role of quantitative NPTX2 hypermethylation as a novel serum diagnostic marker in pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e318221c903↗
  34. Postoperative prognostic predictors of pancreatic ductal adenocarcinoma: clinical analysis and immunoprofile on tissue microarrays. Co-author DOI 10.1245/s10434-012-2277-7↗
  35. Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e3182156d5a↗

Closest collaborators

The 25 strongest of 97 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kyu Taek Lee · 15 shared papers, 2017–2025 · strength 2.24
  2. Jong Kyun Lee · 12 shared papers, 2017–2025 · strength 1.70
  3. Hye Min Kim · 9 shared papers, 2020–2025 · strength 1.30
  4. Jin Seok Heo · 10 shared papers, 2017–2025 · strength 1.21
  5. Kwang Hyuck Lee · 9 shared papers, 2017–2025 · strength 1.16
  6. Joon Oh Park · 8 shared papers, 2018–2025 · strength 0.97
  7. Jin Ho Choi · 5 shared papers, 2024–2025 · strength 0.95
  8. In Woong Han · 6 shared papers, 2020–2025 · strength 0.90
  9. Hongbeom Kim · 7 shared papers, 2020–2025 · strength 0.88
  10. Young Hoon Choi · 5 shared papers, 2023–2025 · strength 0.82
  11. Kee‐Taek Jang · 5 shared papers, 2020–2025 · strength 0.76
  12. Jin‐Young Jang · 8 shared papers, 2017–2023 · strength 0.74
  13. Sang Hyun Shin · 4 shared papers, 2022–2025 · strength 0.70
  14. Wooil Kwon · 7 shared papers, 2017–2023 · strength 0.61
  15. Jung Yong Hong · 3 shared papers, 2022–2025 · strength 0.58
  16. Semin Lee · 3 shared papers, 2024–2025 · strength 0.57
  17. Hee Chul Park · 3 shared papers, 2022–2025 · strength 0.52
  18. Jeong Il Yu · 3 shared papers, 2022–2025 · strength 0.52
  19. Seungyeoun Lee · 6 shared papers, 2017–2023 · strength 0.51
  20. Junghyun Namkung · 6 shared papers, 2017–2023 · strength 0.51
  21. Taesung Park · 6 shared papers, 2017–2023 · strength 0.51
  22. Chang Moo Kang · 6 shared papers, 2017–2023 · strength 0.51
  23. Yoonhyeong Byun · 5 shared papers, 2020–2023 · strength 0.50
  24. Jong Kyun Lee · 3 shared papers, 2020–2025 · strength 0.50
  25. Hyemin Kim · 2 shared papers, 2025–2026 · strength 0.50

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.